{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:33:41Z","timestamp":1787981621601,"version":"build-2784847793"},"reference-count":106,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for 80% of leukemias in this group and about 25% of all cancers. The 5-year survival rate is now over 90%. Achieving such a good outcome is made possible by the introduction of intensive, high-dose chemotherapy. However, it is associated with numerous complications, affecting up to 80% of patients. Among the most common of these are infections and intestinal, hepatic, hematological or neurological complications. For their effective treatment and prevention, it is necessary to develop predictors. High hopes in this aspect are placed on miRNAs. The aim of the following paper is to present the role of miRNAs as predictors of chemotherapy complications in children with ALL. Methods: A systematic review of the available literature in the PubMed, Scopus, Embase and Google Scholar scientific databases was conducted. Fourteen publications were included in the analysis. Results: Changes in miRNA expression and single-nucleotide polymorphisms in miRNAs are associated with complications of ALL therapy. Among the most notable are miR-1206 (in mucositis and myelotoxicity), miR-2053 (in neurotoxicity and mucositis), miR-938 and miR-3117 (in gastrointestinal toxicity and neurotoxicity), miR-1307 (in gastrointestinal toxicity and mucositis) and miR-323b (in gastrointestinal toxicity and myelotoxicity). In addition, miR-155, miR-3117 and miR-4268 may be potential therapeutic targets in complications of ALL therapy. Conclusions: miRNAs are good potential predictors of ALL chemotherapy toxicity and may be therapeutic targets in these complications.<\/jats:p>","DOI":"10.3390\/jcm14165869","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T15:53:37Z","timestamp":1755705217000},"page":"5869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of miRNAs as Predictors of Acute Lymphoblastic Leukemia Chemotherapy Toxicity in Children: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-0441","authenticated-orcid":false,"given":"Ma\u0142gorzata M.","family":"Mitura-Lesiuk","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 6 G\u0119bali Str., 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-8677","authenticated-orcid":false,"given":"Maciej","family":"Dubaj","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3613-3772","authenticated-orcid":false,"given":"Karol","family":"Bigosi\u0144ski","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0359-1086","authenticated-orcid":false,"given":"Mateusz","family":"Raniewicz","sequence":"additional","affiliation":[{"name":"Student Scientific Association, Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ding, F., Deng, L., Xiong, J., Cheng, Z., and Xu, J. (2025). Analysis of global trends in acute lymphoblastic leukemia in children aged 0\u20135 years from 1990 to 2021. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1542649"},{"key":"ref_2","first-page":"e49930","article-title":"A Review of Acute Lymphocytic Leukemia (ALL) in the Pediatric Population: Evaluating Current Trends and Changes in Guidelines in the Past Decade","volume":"15","author":"Ekpa","year":"2023","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, L., Yao, X., and Yang, L. (2025). Global, regional, and national burden of children and adolescents with acute lymphoblastic leukemia from 1990 to 2021: A systematic analysis for the global burden of disease study 2021. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1525751"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hayashi, H., Makimoto, A., and Yuza, Y. (2024). Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective. Cancers, 16.","DOI":"10.3390\/cancers16040723"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Malczewska, M., Ko\u015bmider, K., Bednarz, K., Ostapi\u0144ska, K., Lejman, M., and Zawitkowska, J. (2022). Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14082021"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clml.2020.08.025","article-title":"Acute Complications and Survival Analysis of Childhood Acute Lymphoblastic Leukemia: A 15-year Experience","volume":"21","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_7","first-page":"458","article-title":"Acute complications observed during intensive chemotherapy in pediatric patients with acute lymphoblastic leukemia: Single-center experience","volume":"10","author":"Yildirim","year":"2023","journal-title":"North. Clin. Istanb."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jamaoncol.2024.6812","article-title":"The Children\u2019s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review","volume":"11","author":"DeVine","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00467-017-3662-z","article-title":"Late renal toxicity of treatment for childhood malignancy: Risk factors, long-term outcomes, and surveillance","volume":"33","author":"Skinner","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11899-017-0376-z","article-title":"Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia","volume":"12","author":"Maxwell","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_12","first-page":"610","article-title":"Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia","volume":"198","author":"Egnell","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Denton, C.C., Rawlins, Y.A., Oberley, M.J., Bhojwani, D., and Orgel, E. (2018). Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr. Blood Cancer, 65.","DOI":"10.1002\/pbc.26891"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e29581","DOI":"10.1002\/pbc.29581","article-title":"Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001","volume":"69","author":"Athale","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00280-015-2717-8","article-title":"Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia","volume":"75","author":"Vang","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/cncr.34646","article-title":"Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate","volume":"129","author":"Harris","year":"2023","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mitura-Lesiuk, M.M., Dubaj, M., Dembowska, A., Bigosi\u0144ski, K., and Raniewicz, M. (2024). Hyperleukocytosis in Pediatric Patients with Acute Lymphoblastic Leukemia: Demographic and Clinical Characteristics. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175185"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/erm.12.21","article-title":"Great potential of miRNAs as predictive and prognostic markers for cancer","volume":"12","author":"Cho","year":"2012","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/hematolrep15040065","article-title":"Association of microRNA Polymorphisms with Toxicities Induced by Methotrexate in Children with Acute Lymphoblastic Leukemia","volume":"15","author":"Karpa","year":"2023","journal-title":"Hematol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pgs-2017-0164","article-title":"Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia","volume":"19","author":"Umerez","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Yang, Q.Y., Hu, Y.H., Guo, H.L., Xia, Y., Zhang, Y., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., and Wang, Y.-R. (2021). Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.771487"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/epi-2019-0154","article-title":"miRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review","volume":"12","author":"Astigarraga","year":"2020","journal-title":"Epigenomics"},{"key":"ref_24","first-page":"8941471","article-title":"The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy","volume":"13","author":"Grobbelaar","year":"2019","journal-title":"J. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.enfcli.2019.07.105","article-title":"Prevalence and risk factors of oral mucositis in children with acute lymphoblastic leukemia in Dr. Soetomo Hospital Surabaya Indonesia","volume":"30","author":"Pratiwi","year":"2020","journal-title":"Enfermer\u00eda Cl\u00ednica"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ribeiro, I.L.A., Limeira, R.R.T., Dias de Castro, R., Ferreti Bonan, P.R., and Valen\u00e7a, A.M.G. (2017). Oral Mucositis in Pediatric Patients in Treatment for Acute Lymphoblastic Leukemia. Int. J. Environ. Res. Public Health, 14.","DOI":"10.3390\/ijerph14121468"},{"key":"ref_28","first-page":"1648","article-title":"Management of oral mucositis in children","volume":"26","author":"Alqahtani","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez, E., Guti\u00e9rrez-Camino, \u00c1., Pi\u00f1\u00e1n, M.\u00c1., S\u00e1nchez-Toledo, J., Uriz, J.J., Ballesteros, J., Garc\u00eda-Miguel, P., Navajas, A., and Garc\u00eda-Orad, \u00c1. (2014). Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091261"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhan, M., Liu, T., Zhang, Z., Wang, G., Cao, Z., Li, X., Zeng, H., Mai, H., and Chen, Z. (2023). Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1153767"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101392","DOI":"10.1016\/j.genrep.2021.101392","article-title":"MiR-1307: A comprehensive review of its role in various cancer","volume":"25","author":"Saberianpour","year":"2021","journal-title":"Gene Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0000000000000291","article-title":"The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia","volume":"27","author":"Oosterom","year":"2017","journal-title":"Pharmacogenet. Genom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2217\/pgs-2017-0164","article-title":"Involvement of miRNA Polymorphism in Mucositis Development in Childhood Acute lymphoblastic Leukemia Treatment","volume":"19","author":"Umerez","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2543070","DOI":"10.1155\/2016\/2543070","article-title":"Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease","volume":"2016","author":"Zhou","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"da Silva Menezes, E., de Moraes, F.C.A., de Nazar\u00e9 Cohen-Paes, A., Wanderley, A.V., Pereira, E.E.B., Pastana, L.F., Modesto, A.A.C., de Assump\u00e7\u00e3o, P.P., Burbano, R.M.R., and Dos Santos, S.E.B. (2023). Influence of Genetic Variations in miRNA and Genes Encoding Proteins in the miRNA Synthesis Complex on Toxicity of the Treatment of Pediatric B-Cell ALL in the Brazilian Amazon. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054431"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wan, X., Wang, L., Wang, Z., and Wan, C. (2024). Toll-like receptor 4 plays a vital role in irritable bowel syndrome: A scoping review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1490653"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1356","DOI":"10.1002\/iid3.1356","article-title":"Interactions between toll-like receptors signaling pathway and gut microbiota in host homeostasis","volume":"12","author":"Chen","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yang, Y., Zhou, W., Xu, X., Ge, X., Wang, F., Zhang, G.Q., Miao, L., and Deng, X. (2022). Aprepitant Inhibits JNK and p38\/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.811584"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s43042-024-00562-x","article-title":"Relationship between the efficacy and adverse effects of methotrexate and gene polymorphism","volume":"25","author":"Zhao","year":"2024","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Taylor, Z.L., Vang, J., Lopez-Lopez, E., Oosterom, N., Mikkelsen, T., and Ramsey, L.B. (2021). Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies. Cancers, 13.","DOI":"10.3390\/cancers13112837"},{"key":"ref_41","first-page":"8216","article-title":"Influence of variants of the drosha, mir499a, and mir938 genes on susceptibility to acute lymphoblastic leukemia in an admixed population from the brazilian amazon","volume":"12","author":"Wanderley","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/pme-2021-0001","article-title":"miR-938rs2505901 T>C polymorphism increases Hirschsprung disease risk: A case-control study of Chinese children","volume":"18","author":"Zhong","year":"2021","journal-title":"Pers. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rashid, H., Hossain, B., Siddiqua, T., Kabir, M., Noor, Z., Ahmed, M., and Haque, R. (2020). Fecal MicroRNAs as Potential Biomarkers for Screening and Diagnosis of Intestinal Diseases. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00181"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Barrios-Palacios, D., Organista-Nava, J., Balandr\u00e1n, J.C., Alarc\u00f3n-Romero, L.d.C., Zubillaga-Guerrero, M.I., Illades-Aguiar, B., Rivas-Alarc\u00f3n, A.A., Diaz-Lucas, J.J., G\u00f3mez-G\u00f3mez, Y., and Leyva-V\u00e1zquez, M.A. (2023). The Role of miRNAs in Childhood Acute Lymphoblastic Leukemia Relapse and the Associated Molecular Mechanisms. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010119"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2478\/ahp-2020-0029","article-title":"Acute non-hematological toxicity of intensive chemotherapy of acute lymphoblastic leukemia in children","volume":"51","author":"Demidowicz","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/epi-2017-0138","article-title":"Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity","volume":"10","author":"Umerez","year":"2018","journal-title":"Epigenomics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.629","article-title":"Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy","volume":"102","author":"Liu","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3945\/ajcn.114.086603","article-title":"High folic acid consumption leads to pseudo-MTHFR deficiency, altered lipid metabolism, and liver injury in mice","volume":"101","author":"Christensen","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ali, A.M., Adam, H., Hailu, D., Engidawork, E., Howe, R., Abula, T., and Coenen, M.J.H. (2023). Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1159307"},{"key":"ref_50","first-page":"358","article-title":"Effects of Reduced Mir-24 Expression on Plasma Methotrexate Levels, Therapy-Related Toxicities, and Patient Outcomes in Pediatric Acute Lymphoblastic Leukemia","volume":"8","author":"Esmaili","year":"2020","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3892\/or.2015.3787","article-title":"High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia","volume":"33","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"19971","DOI":"10.1073\/pnas.0709313104","article-title":"MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia","volume":"104","author":"Mi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.0706217104","article-title":"A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance","volume":"104","author":"Mishra","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ajpath.2017.02.016","article-title":"miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis","volume":"187","author":"Yuan","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e926","DOI":"10.1161\/CIR.0000000000001308","article-title":"Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association","volume":"151","author":"Ryan","year":"2025","journal-title":"Circulation"},{"key":"ref_56","first-page":"8828410","article-title":"Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment","volume":"2021","author":"Blag","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Meo, L., Savarese, M., Munno, C., Mirabelli, P., Ragno, P., Leone, O., and Alfieri, M. (2023). Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122712"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e004653","DOI":"10.1161\/JAHA.116.004653","article-title":"Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy","volume":"6","author":"Leger","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.crvasa.2018.03.008","article-title":"Role of serum microRNA-499 as a diagnostic marker in acute myocardial infarction","volume":"61","author":"Vengatapathy","year":"2019","journal-title":"Cor Vasa"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.18632\/aging.203997","article-title":"miRNA-29 aggravates myocardial infarction via inhibiting the PI3K\/mTOR\/HIF1\u03b1\/VEGF pathway","volume":"14","author":"Wang","year":"2022","journal-title":"Aging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41390-020-1049-5","article-title":"Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment","volume":"89","author":"Cheung","year":"2021","journal-title":"Pediatr. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6994","DOI":"10.18632\/oncotarget.14355","article-title":"Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"8","author":"Rigaud","year":"2017","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaccao.2023.12.009","article-title":"Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Boen","year":"2024","journal-title":"JACC Cardio Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e012150","DOI":"10.1161\/CIRCEP.123.012150","article-title":"MicroRNA-1 Deficiency Is a Primary Etiological Factor Disrupting Cardiac Contractility and Electrophysiological Homeostasis","volume":"17","author":"Yang","year":"2024","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"H1443","DOI":"10.1152\/ajpheart.00252.2018","article-title":"Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy","volume":"315","author":"Oatmen","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Antoniadi, K., Thomaidis, N., Nihoyannopoulos, P., Toutouzas, K., Gikas, E., Kelaidi, C., and Polychronopoulou, S. (2023). Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies. Diagnostics, 13.","DOI":"10.20944\/preprints202304.0746.v2"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00467-024-06331-7","article-title":"Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia","volume":"39","author":"Petgrave","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e30696","DOI":"10.1002\/pbc.30696","article-title":"Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN)","volume":"70","author":"Hsiao","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"818","DOI":"10.12659\/MSM.897187","article-title":"Inhibiting microRNA-449 Attenuates Cisplatin-Induced Injury in NRK-52E Cells Possibly via Regulating the SIRT1\/P53\/BAX Pathway","volume":"22","author":"Qin","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40246-016-0085-z","article-title":"MicroRNAs in acute kidney injury","volume":"10","author":"Fan","year":"2016","journal-title":"Hum. Genom."},{"key":"ref_71","first-page":"199","article-title":"TPMT Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy","volume":"14","author":"Rosdiana","year":"2021","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lee, J.M., Shim, Y.J., Kim, D.H., Jung, N., and Ha, J.S. (2021). The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia. Children, 8.","DOI":"10.3390\/children8030224"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ali, A.M., Adam, H., Hailu, D., Coenen, M.J.H., Howe, R., and Abula, T. (2023). Incidence and determinants of hematotoxicity in acute lymphoblastic leukemia children who received 6-mercaptopurine based maintenance therapy in Addis Ababa, Ethiopia. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0286544"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3892\/ol.2013.1234","article-title":"Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma","volume":"5","author":"Ouyang","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_75","first-page":"78829","article-title":"Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol","volume":"4","author":"Kar","year":"2017","journal-title":"Open Access Libr. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.21873\/invivo.11608","article-title":"Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia","volume":"33","author":"Zawitkowska","year":"2019","journal-title":"In Vivo"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/pbc.22719","article-title":"Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia","volume":"56","author":"Lund","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Jantararoungtong, T., Wiwattanakul, S., Tiyasirichokchai, R., Prommas, S., Sukprasong, R., Koomdee, N., Jinda, P., Rachanakul, J., Nuntharadthanaphong, N., and Pakakasama, S. (2021). TPMT*3C as a Predictor of 6-Mercaptopurine-Induced Myelotoxicity in Thai Children with Acute Lymphoblastic Leukemia. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080783"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1002\/jcb.26800","article-title":"MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia","volume":"119","author":"Ghodousi","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/pr.2014.43","article-title":"Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility","volume":"75","author":"Uriz","year":"2014","journal-title":"Pediatr. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zheng, Q., Jiang, C., Liu, H., Hao, W., Wang, P., Huang, H., Li, Z., Qian, J., Qian, M., and Zhang, H. (2020). Down-Regulated FOXO1 in Refractory\/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.579673"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"104260","DOI":"10.1016\/j.cellimm.2020.104260","article-title":"MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment","volume":"360","author":"Mudd","year":"2021","journal-title":"Cell. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.currproblcancer.2021.100758","article-title":"Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China","volume":"45","author":"Jia","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Kyriakidis, K., and Tsezou, A. (2022). MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools. Cancers, 14.","DOI":"10.3390\/cancers14163976"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Yazarlou, F., Kadkhoda, S., and Ghafouri-Fard, S. (2021). Emerging role of let-7 family in the pathogenesis of hematological malignancies. Biomed. Pharmacother., 144.","DOI":"10.1016\/j.biopha.2021.112334"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: Methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_87","first-page":"295","article-title":"Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia","volume":"13","author":"Maamari","year":"2020","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apa.17092","article-title":"Chemotherapy-related toxicities follow a typical pattern in children treated for acute lymphoblastic leukaemia","volume":"113","author":"Rokkanen","year":"2024","journal-title":"Acta Paediatr."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kranj\u010dec, I., Raja\u010di\u0107, N., Janji\u0107, T., Kukuruzovi\u0107, M., Jadrijevi\u0107-Cvrlje, F., Pavlovi\u0107, M., and Roganovi\u0107, J. (2024). Acute Neurotoxicity in Children Treated for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: A 10-Year Single-Centre Experience. Children, 12.","DOI":"10.3390\/children12010031"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"\u015aliwa-Tytko, P., Kaczmarska, A., Lejman, M., and Zawitkowska, J. (2022). Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105515"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2020.268565","article-title":"Methotrexate-related central neurotoxicity: Clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia","volume":"107","author":"Mateos","year":"2022","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"111240","DOI":"10.1016\/j.brainresbull.2025.111240","article-title":"MicroRNA-155 modulates methotrexate-induced spatial memory impairment by disruption of the blood-brain barrier integrity","volume":"222","author":"Chen","year":"2025","journal-title":"Brain Res. Bull."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/WNR.0000000000001382","article-title":"Mir-155 knockout protects against ischemia\/reperfusion-induced brain injury and hemorrhagic transformation","volume":"31","author":"Suofu","year":"2020","journal-title":"Neuroreport"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41397-017-0003-3","article-title":"Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia","volume":"18","author":"Umerez","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Pavlovic, S., Kotur, N., Stankovic, B., Zukic, B., Gasic, V., and Dokmanovic, L. (2019). Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. Genes, 10.","DOI":"10.3390\/genes10030191"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41397-019-0081-5","article-title":"Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia","volume":"19","author":"Astigarraga","year":"2019","journal-title":"Pharmacogenom. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13046-025-03312-y","article-title":"Targeting TUBB2B inhibits triple-negative breast cancer growth and brain-metastatic colonization","volume":"44","author":"He","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12935-019-1082-9","article-title":"miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma","volume":"19","author":"Mao","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jocn.2019.11.043","article-title":"Up-regulation of Sirt1\/miR-149-5p signaling may play a role in resveratrol induced protection against ischemia via p53 in rat brain","volume":"72","author":"Teertam","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12967-020-02415-8","article-title":"MicroRNA-181a as novel liquid biopsy marker of central nervous system involvement in pediatric acute lymphoblastic leukemia","volume":"18","author":"Egyed","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1610096","DOI":"10.3389\/pore.2022.1610096","article-title":"Co-Detection of VEGF-A and Its Regulator, microRNA-181a, May Indicate Central Nervous System Involvement in Pediatric Leukemia","volume":"28","author":"Egyed","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Condrat, C.E., Thompson, D.C., Barbu, M.G., Bugnar, O.L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S.M., and Voinea, S.C. (2020). miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells, 9.","DOI":"10.3390\/cells9020276"},{"key":"ref_103","first-page":"32","article-title":"Secretory miRNAs as novel cancer biomarkers","volume":"1826","author":"Zhang","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1039\/C8AN01572D","article-title":"Molecular methods in electrochemical microRNA detection","volume":"144","author":"Gillespie","year":"2018","journal-title":"Analyst"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41388-024-03076-3","article-title":"MicroRNAs: Circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances","volume":"43","author":"Metcalf","year":"2024","journal-title":"Oncogene"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:31:31Z","timestamp":1760034691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":106,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14165869"],"URL":"https:\/\/doi.org\/10.3390\/jcm14165869","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}